You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-PD1 failed

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • PD-1 Inhibitors
  • Zhengzhou, Henan, China
    Feng Wang
Oct 9, 2023

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion；Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

Melanoma Stage III, Melanoma Stage IV, Inoperable Disease Trial in Tampa (Interleukin-2, Ipilimumab, Nivolumab)

Recruiting
  • Melanoma Stage III
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 6, 2022

Local Progression or Metastatic Melanoma With Failed First-line Treatment Trial in Beijing (Pexa-Vec combined with ZKAB001,

Recruiting
  • Local Progression or Metastatic Melanoma With Failed First-line Treatment
  • Pexa-Vec combined with ZKAB001
  • ZKAB001 monotherapy
  • Beijing, China
    Beijing Cancer Hospital
Mar 30, 2022

Merkel Cell Carcinoma Trial in Worldwide (KRT-232, Avelumab)

Recruiting
  • Merkel Cell Carcinoma
  • Aurora, Colorado
  • +38 more
Aug 3, 2022

Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)

Enrolling by invitation
  • Malignant Melanomas
  • Recombinant Human Adenovirus Type 5 Injection
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital, Department of Internal Medicine, Ward 19
Jul 7, 2023

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Oligometastatic Disease
    • PD-1 combined with SBRT
    • Guangzhou, Guangdong, China
      Mian Xi
    Dec 18, 2022

    Immunotherapy, ADR Trial in Beijing

    Not yet recruiting
    • Immunotherapy
    • ADR
      • Beijing, Beijing, China
        Xuanwu Hospital
      Jan 27, 2023

      Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • Neoadjuvant Chemoimmunotherapy
      • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
      • (no location specified)
      Feb 14, 2023

      Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

      Recruiting
      • Melanoma (Skin)
      • +4 more
      • Bloomington, Minnesota
      • +7 more
      Jan 31, 2023

      Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • +3 more
      • Low-Dose Decitabine plus anti-PD-1
      • Beijing, Beijing, China
        ChinaPLAGH
      Apr 18, 2023

      NSCLC, Immunotherapy Trial in Ann Arbor (Dexamthasone)

      Terminated
      • Non-Small Cell Lung Cancer
      • Immunotherapy
      • Ann Arbor, Michigan
        VA Ann Arbor Healthcare System, Ann Arbor, MI
      Jan 6, 2023

      Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

      Not yet recruiting
      • Nasopharyngeal Carcinoma
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Oct 31, 2023

      Metastasis, Solid Tumor Trial (Peptide Alarm Therapy (PAT))

      Not yet recruiting
      • Metastasis
      • Solid Tumor
      • Peptide Alarm Therapy (PAT)
      • (no location specified)
      Nov 2, 2022

      Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

      Not yet recruiting
      • Solid Tumor, Adult
      • +2 more
      • (no location specified)
      Dec 14, 2022

      Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

      Not yet recruiting
      • Lung Neoplasm
      • +2 more
      • Tumor samples
      • Bordeaux, France
        CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
      Aug 28, 2023

      Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

      Recruiting
      • Nasopharyngeal Carcinoma
      • Anti-EGFR and PD-1 inhibitor arm
      • Shanghai, Shanghai, China
        Eye & ENT Hospital of Fudan University
      Nov 26, 2023

      Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

      Completed
      • Metastatic Colorectal Adenocarcinoma
      • regorafenib plus anti-PD-1 antibodies
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Jul 4, 2023

      Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

      Not yet recruiting
      • Stage IIIA Hepatocellular Carcinoma
      • Radiotherapy combined with TKI and Anti-PD-1 Antibody
      • (no location specified)
      Sep 24, 2023

      Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

      Recruiting
      • Hepatocellular Carcinoma
      • Shanghai, China
        Zhongshan Hospital Fudan university
      Jan 31, 2023

      Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

      Not yet recruiting
      • Muscle-Invasive Bladder Carcinoma
      • +2 more
      • Guangzhou, Guangdong, China
        Cancer Center, Sun Yat-sen University
      Aug 3, 2023